Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials.
The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. Thousands of regimens have been employed for the eradication of this deadly disease and yet the new interventions are anticipated. Undeniably, several modalities have resulted in some form of relief so far, but the triumph towards cancer abolition is long way road.
The conventional chemotherapy and radiotherapy have limited therapeutic index and a plethora of treatment associated negative effects. The current scenario of the oncological treatment represents the impetus search for the novel therapeutic modalities that can selectively disrupt the tumor cells and block the cancer growth along with the safety, that the treatment will be harmless towards the normal cells.
The major role of developing the new therapy for the treatment of cancer is to have broader therapeutic index which represents the high potency towards the malignant cells with low or no toxicities towards healthy cells. One such approach is the use of the viruses for the treatment of cancer turning into term known as viral oncotherapy. With the advances in oncology and the virology, the routes towards the engineering of viruses with increased tumor selectivity and enhanced oncolytic activity is conceivable.
Therefore the oncolytic virus is a virus that preferentially infects and kills cancer cells, as the infected cancer cells are destroyed by oncolysis, they release new infectious viral particles to help destroy the remaining tumor. Oncolytic viruses perform the dual functions they not only cause the destruction of cancerous cell but also stimulate the host anti-tumor immune responses and don’t allow the growth of tumor cells. Certainly, targeted therapy of cancer using viruses has generated interest in the light of limited efficacy of the standard cancer therapeutics.
The next few years will see progress in terms of viral delivery, in particular the use of immune cell carriers that have yet to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combinations of viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies will probably be tested in early phase clinical trials.
For the broader future of oncolytic immunotherapy, it is expected that a rapid expansion of the number of clinical trials already being conducted combining this with immune co-inhibitory pathway blockade, improved oncolytic agents being developed (i.e. with greater direct antitumor effects and with an improved ability to spread through tumors), and in particular the ability of viruses to deliver proteins directly to the tumor microenvironment to help further induce, enhance, and shape the anti-tumor immune response being exploited to a greater extent.
“Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials.
The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. Thousands of regimens have been employed for the eradication of this deadly disease and yet the new interventions are anticipated. Undeniably, several modalities have resulted in some form of relief so far, but the triumph towards cancer abolition is long way road.
The conventional chemotherapy and radiotherapy have limited therapeutic index and a plethora of treatment associated negative effects. The current scenario of the oncological treatment represents the impetus search for the novel therapeutic modalities that can selectively disrupt the tumor cells and block the cancer growth along with the safety, that the treatment will be harmless towards the normal cells.
The major role of developing the new therapy for the treatment of cancer is to have broader therapeutic index which represents the high potency towards the malignant cells with low or no toxicities towards healthy cells. One such approach is the use of the viruses for the treatment of cancer turning into term known as viral oncotherapy. With the advances in oncology and the virology, the routes towards the engineering of viruses with increased tumor selectivity and enhanced oncolytic activity is conceivable.
Therefore the oncolytic virus is a virus that preferentially infects and kills cancer cells, as the infected cancer cells are destroyed by oncolysis, they release new infectious viral particles to help destroy the remaining tumor. Oncolytic viruses perform the dual functions they not only cause the destruction of cancerous cell but also stimulate the host anti-tumor immune responses and don’t allow the growth of tumor cells. Certainly, targeted therapy of cancer using viruses has generated interest in the light of limited efficacy of the standard cancer therapeutics.
The next few years will see progress in terms of viral delivery, in particular the use of immune cell carriers that have yet to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combinations of viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies will probably be tested in early phase clinical trials.
For the broader future of oncolytic immunotherapy, it is expected that a rapid expansion of the number of clinical trials already being conducted combining this with immune co-inhibitory pathway blockade, improved oncolytic agents being developed (i.e. with greater direct antitumor effects and with an improved ability to spread through tumors), and in particular the ability of viruses to deliver proteins directly to the tumor microenvironment to help further induce, enhance, and shape the anti-tumor immune response being exploited to a greater extent.
1. PROLOGUE TO ONCOLYTIC VIRUS
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
2. PRIMER OF VIROTHERAPY IN MALIGNANCIES
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
3. MECHANISM INVOLVED IN VIRAL ONCOLYSIS
3.1 Viral Entry into Cancerous Cells
3.2 Efficacy Routes Followed by Oncogenic Viruses
3.3 Mechanism of Tumor Specificity
3.3.1 Defective Anti-Viral Responses
3.3.2 Receptor Targeting for Tumor Selective Intake
3.3.3 Targeting to Tumor Specific Promoters
3.3.4 Viral Gene Deletions
3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment
4. CANCER IMMUNOTHERAPY BY ONCOLYTIC VIRUSES
4.1 Stimulation of Antitumor Immune Responses
4.2 Oncolytic Viruses as Cancer Vaccines
5. VARIETIES OF VIRUSES CASTED AS ONCOLYTIC VIRUSES
5.1 Oncolytic Wild Type Viruses
5.1.1 Reovirus (Respiratory Enteric Orphan Virus)
5.1.2 Vesicular Stomatitis Virus (VSV)
5.1.3 Newcastle Disease Virus (NDV)
5.1.4 Myxoma
5.2 Genetically Engineered Oncolytic Viruses
5.2.1 Adenoviruses
5.2.2 Herpes Simplex Virus
5.2.3 Vaccinia Virus
6. APPROVED ONCOLYTIC VIRUS THERAPEUTICS
6.1 Onxy-15
6.2 RIGVIR
6.3 Talimogene laherparepvec (T-VEC)
6.4 Reolysin
7. POTENTIAL ONCOLYTIC VIRUSES FOR CANCERS
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Melanoma
7.5 Brain Tumor
7.6 Blood Cancer
8. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET OVERVIEW
8.1 Preface towards Oncolytic Virus Arcade
8.2 Market Aspects of Approved Oncolytic Viruses
8.3 Oncolytic Virus Clinical Pipeline Overview
9. ONCOLYTIC VIRUS MARKET DYNAMICS
9.1 Accelerative Parameters
9.2 Major Challenges Faced by Oncolytic Virus
10. FUTURE ASPECTS OF ONCOLYTIC VIRAL THERAPY
11. GLOBAL ONCOLYTIC VIRUS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III
12. MARKETED ONCOLYTIC VIRUS CLINICAL INSIGHT BY COMPANY & INDICATION
12.1 Talimogene Laherparepvec (IMLYGIC)
12.2 H 101 (Oncorine)
13. NO DEVELOPMENT REPORTED ONCOLYTIC VIRUS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
13.1 No Development Reported
13.2 Discontinued
14. COMPETITIVE LANDSCAPE
14.1 BioVex
14.2 Cell Genesys
14.3 Crusade Laboratories
14.4 Genelux Corporation
14.5 Jennerex Biotherapeutics
14.6 Lokon Pharma
14.7 Merck
14.8 MultiVir
14.9 Oncolys BioPharma
14.10 Oncolytics Biotech
14.11 Oncos Therapeutics
14.12 PsiOxus Therapeutics
14.13 Shanghai Sunway Bioteh
14.14 Takara Bio
14.15 VCN Biosciences
14.16 ViroTarg
14.17 Vyriad
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
2. PRIMER OF VIROTHERAPY IN MALIGNANCIES
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
3. MECHANISM INVOLVED IN VIRAL ONCOLYSIS
3.1 Viral Entry into Cancerous Cells
3.2 Efficacy Routes Followed by Oncogenic Viruses
3.3 Mechanism of Tumor Specificity
3.3.1 Defective Anti-Viral Responses
3.3.2 Receptor Targeting for Tumor Selective Intake
3.3.3 Targeting to Tumor Specific Promoters
3.3.4 Viral Gene Deletions
3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment
4. CANCER IMMUNOTHERAPY BY ONCOLYTIC VIRUSES
4.1 Stimulation of Antitumor Immune Responses
4.2 Oncolytic Viruses as Cancer Vaccines
5. VARIETIES OF VIRUSES CASTED AS ONCOLYTIC VIRUSES
5.1 Oncolytic Wild Type Viruses
5.1.1 Reovirus (Respiratory Enteric Orphan Virus)
5.1.2 Vesicular Stomatitis Virus (VSV)
5.1.3 Newcastle Disease Virus (NDV)
5.1.4 Myxoma
5.2 Genetically Engineered Oncolytic Viruses
5.2.1 Adenoviruses
5.2.2 Herpes Simplex Virus
5.2.3 Vaccinia Virus
6. APPROVED ONCOLYTIC VIRUS THERAPEUTICS
6.1 Onxy-15
6.2 RIGVIR
6.3 Talimogene laherparepvec (T-VEC)
6.4 Reolysin
7. POTENTIAL ONCOLYTIC VIRUSES FOR CANCERS
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Melanoma
7.5 Brain Tumor
7.6 Blood Cancer
8. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET OVERVIEW
8.1 Preface towards Oncolytic Virus Arcade
8.2 Market Aspects of Approved Oncolytic Viruses
8.3 Oncolytic Virus Clinical Pipeline Overview
9. ONCOLYTIC VIRUS MARKET DYNAMICS
9.1 Accelerative Parameters
9.2 Major Challenges Faced by Oncolytic Virus
10. FUTURE ASPECTS OF ONCOLYTIC VIRAL THERAPY
11. GLOBAL ONCOLYTIC VIRUS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III
12. MARKETED ONCOLYTIC VIRUS CLINICAL INSIGHT BY COMPANY & INDICATION
12.1 Talimogene Laherparepvec (IMLYGIC)
12.2 H 101 (Oncorine)
13. NO DEVELOPMENT REPORTED ONCOLYTIC VIRUS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
13.1 No Development Reported
13.2 Discontinued
14. COMPETITIVE LANDSCAPE
14.1 BioVex
14.2 Cell Genesys
14.3 Crusade Laboratories
14.4 Genelux Corporation
14.5 Jennerex Biotherapeutics
14.6 Lokon Pharma
14.7 Merck
14.8 MultiVir
14.9 Oncolys BioPharma
14.10 Oncolytics Biotech
14.11 Oncos Therapeutics
14.12 PsiOxus Therapeutics
14.13 Shanghai Sunway Bioteh
14.14 Takara Bio
14.15 VCN Biosciences
14.16 ViroTarg
14.17 Vyriad
LIST OF FIGURES
Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy
Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 3-1: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 3-2: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 3-3: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 3-4: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
Figure 4-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
Figure 5-1: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 5-2: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 5-3: Mechanism of Oncolytic Behavior of Adenoviruses
Figure 6-1: Mechanism of Action of T-VEC in Treating Melanoma Cancer
Figure 7-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 7-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
Figure 8-1: Global Oncolytic Virus Pipeline by Phase (%), 2016 till 2022
Figure 8-2: Oncolytic Virus Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-3: Oncolytic Virus Drugs No Development Reported & Discontinued in Clinical Pipeline by Phase (%), 2016 till 2022
Figure 8-4: Oncolytic Virus Drugs No Development Reported & Discontinued in Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 9-1: Major Drivers for the Oncolytic Virus Therapies
Figure 9-2: Major Challenges Faced by Oncolytic Viral Therapies
Figure 14-1: Crusade Laboratories - Clinical Pipeline
Figure 14-2: Lokon Pharma - Clinical Pipeline
Figure 14-3: Merck - Clinical Pipeline
Figure 14-4: MultiVir –Clinical Pipeline
Figure 14-5: Oncolys BipoPharma - Clinical Pipeline
Figure 14-6: Oncos Therapeutics - Clinical stage
Figure 14-7: Vyriad - Clinical Pipeline
Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy
Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 3-1: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 3-2: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 3-3: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 3-4: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
Figure 4-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
Figure 5-1: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 5-2: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 5-3: Mechanism of Oncolytic Behavior of Adenoviruses
Figure 6-1: Mechanism of Action of T-VEC in Treating Melanoma Cancer
Figure 7-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 7-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
Figure 8-1: Global Oncolytic Virus Pipeline by Phase (%), 2016 till 2022
Figure 8-2: Oncolytic Virus Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-3: Oncolytic Virus Drugs No Development Reported & Discontinued in Clinical Pipeline by Phase (%), 2016 till 2022
Figure 8-4: Oncolytic Virus Drugs No Development Reported & Discontinued in Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 9-1: Major Drivers for the Oncolytic Virus Therapies
Figure 9-2: Major Challenges Faced by Oncolytic Viral Therapies
Figure 14-1: Crusade Laboratories - Clinical Pipeline
Figure 14-2: Lokon Pharma - Clinical Pipeline
Figure 14-3: Merck - Clinical Pipeline
Figure 14-4: MultiVir –Clinical Pipeline
Figure 14-5: Oncolys BipoPharma - Clinical Pipeline
Figure 14-6: Oncos Therapeutics - Clinical stage
Figure 14-7: Vyriad - Clinical Pipeline
